EU green light for Novartis’ Rydapt

20th September 2017 Uncategorised 0

The European Commission has approved Novartis’ Rydapt to treat a certain form of acute myeloid leukaemia (AML) as well as three other rare diseases.

More: EU green light for Novartis’ Rydapt
Source: News